Influence of Atorvastatin on Apolipoprotein E and AI Kinetics in Patients with Type 2 Diabetes
- 1 October 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 315 (1) , 363-369
- https://doi.org/10.1124/jpet.105.085522
Abstract
Atorvastatin reduces both plasma cholesterol and triglyceride concentrations in patients with type 2 diabetes, but mechanisms underlying triglyceride decrease and the effect of atorvastatin on high density lipoprotein (HDL) still remain unclear. Apolipoprotein (apo) E plays a crucial role in modulating production and clearance of triglyceride-rich very low density lipoprotein (VLDL). The main effect of apoAI is to modulate HDL metabolism. The aim of this work was to study the influence of atorvastatin on apoAI and apoE kinetics and to determine whether its hypocholesterolemic and hypotriglyceridemic effects could be related to changes in this apolipoprotein metabolism. Plasma VLDL-apoE, HDL-apoE, and HDL-apoAI were studied in seven patients with diabetes with mixed hyperlipidemia using a stable isotope labeling technique ([2H3]leucine-primed constant infusion) and monocompartmental model before and after 2 months of treatment with 40 mg/day of atorvastatin. Plasma apoE concentration was significantly reduced (44.1 ± 19.1 versus 32 ± 11.6 mg/l, p < 0.05) after treatment. This decrease was associated with a diminution of HDL-apoE concentration (17.46 ± 6.71 versus 13.37 ± 6.05 mg/l, p < 0.05) and production rate (0.202 ± 0.085 versus 0.119 ± 0.047 mg/kg/day, p < 0.05), whereas an increase in VLDL-apoE concentration (6.44 ± 2.16 before versus 9.23 ± 4.02 mg/l after, p < 0.05) and production rate (0.827 ± 0.367 versus 1.524 ± 0.664 mg/kg/day, p < 0.05) was observed. No significant difference was observed after treatment for apoAI parameters. We conclude that atorvastatin treatment promotes different apoE distribution between HDL and VLDL, favoring VLDL apoE content. The increased number of apoE per VLDL particle suggests that atorvastatin could enhance the direct catabolism of triglyceride-rich VLDL through apoE receptor pathways.Keywords
This publication has 40 references indexed in Scilit:
- Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?Current Opinion in Lipidology, 2003
- Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 DiabetesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetesInternational Journal of Obesity, 2002
- Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral ObesityJournal of Clinical Endocrinology & Metabolism, 2002
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Lipoprotein Lipase Binds to Low Density Lipoprotein Receptors and Induces Receptor-mediated Catabolism of Very Low Density LipoproteinsPublished by Elsevier ,1996
- Lipoprotein metabolism in diabetesCurrent Opinion in Lipidology, 1994
- Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among the plasma lipoproteinsAtherosclerosis, 1988
- Apolipoprotein E phenotyping from serum by Western blottingElectrophoresis, 1986
- Apoprotein composition of very low density lipoproteins of human serum.Journal of Clinical Investigation, 1975